← Back to headlines
NRx Pharmaceuticals Files 10-K, Highlights Operational Progress and Q4 Earnings
NRx Pharmaceuticals announced its Q4 GAAP EPS of -$1.34 and revenue of $1.23 million, with further details highlighted during its earnings call, and has now filed its 2025 Form 10-K, emphasizing operational progress.
24 Mar, 15:55 — 24 Mar, 15:55
Related Stories
Philippines Health Secretary Herbosa calls expired medicine complaints a 'demolition job'
just now
PhilHealth eyes accreditation of pediatric neurologists for autism care
just now
FG, Senator Unveil Hepatitis Intervention for Southern Kaduna Residents
10m ago
Nigerian Celebrity Phyna Undergoes BBL Surgery
12m ago